BioSpace News Archive

The company is making great progress with delivering on the strategic priorities we defined on Day 1 of Idorsia.

Artios Pharma Limited, a leading DNA Damage Response company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, announced the completion of a US$153 million Series C financing to fund further development of its promising clinical-stage pipeline.

Veterinary dermatology is also referred as pet skin care, it is diagnosis, treatment, and prevention of skin problems in animals.

New covalent bonds between two molecules are created by the enzyme called ligase. Same as all enzymes, ligases are embedded with proteins that have a target molecule identification site.

The global intraocular lens market is expected to be on course to achieve considerable growth in the coming years of the forecast period.

The acute repetitive seizure is a condition that occurs in patients with drug-refractory epilepsy. It is also known as cluster seizure, seizure flurry, breakthrough seizure, seizure cluster, serial seizure, or prolonged seizure.

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that it will present new data establishing the feasibility of using transplanted human organoids to assess the pharmacodynamic (PD) efficacy of novel therapeutic candidates, including GFB-887, at the 13th International Podocyte Conference, taking place July 27-31, 2021, online and at the University of Manchester, UK.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the market.

Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021.

BioFlyte, a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced the formation of a Scientific Advisory Board (SAB).